Evidence map›Paper›PMID 31217689›Full record

ArticleCancer informatics2019

Leveraging Image-Derived Phenotypic Measurements for Drug-Target Interaction Predictions.

Srikanth Kuthuru, Adam T Szafran, Fabio Stossi, Michael A Mancini, Arvind Rao

Open access · goldAbstract read
In one paragraph

Article in Cancer informatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Frontiers in pharmacology · 2024
    Article
  2. Review
  3. Article
  4. Frontiers in chemistry · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Srikanth KuthuruDepartment of Electrical and Computer Engineering, Rice University, Houston, TX, USA.
Adam T SzafranDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Fabio StossiDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Michael A ManciniDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Arvind RaoDepartment of Electrical and Computer Engineering, Rice University, Houston, TX, USA.
Baylor College of Medicine · USUniversity of Michigan–Ann Arbor · USTexas A&M University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Synthesizing Image-derived Heterogeneity with Genomic measurements for Assessing Disease Aggressiveness in Lower Grade GliomasR37CA214955 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURTEK, SEBASTIAN, RAO, ARVIND · 2018 to 2024
$3.9M
NCI NIH HHS P30 CA016672NCI NIH HHS R37 CA214955
6 · The paper itself

Abstract

In recent years, protein kinases have become some of the most significant drug targets in cancer patients. Kinases are known to regulate the activity of many human proteins, and consequently their inhibition has been used to control cancer proliferation. A significant challenge in drug discovery is the rapid and efficient identification of new small molecules. In this study, we propose a novel in silico drug discovery approach to identify kinase targets that impinge on nuclear receptor signaling with data generated using high-content analysis (HCA). A high-throughput imaging dataset was generated from an siRNA human kinome screen on engineered cells that allow direct visualization of effects on estrogen receptor-α or a chimeric progesterone receptor B binding to specific DNA. Two types of kinase descriptors are extracted from these imaging data: first, a population-median-based descriptor and second a bag-of-words (BoW) descriptor that can capture heterogeneity information in the imaging data. Using these descriptors, we provide prediction results of drug-kinase-target interactions based on single-task learning, multi-task learning, and collaborative filtering methods. The best performing model in target-based drug discovery gives an area under the receiver operating characteristic curve (AUC) of 0.86, whereas the best model in ligand-based discovery gives an AUC of 0.79. These promising results suggest that imaging-based information can be used as an additional source of information to existing virtual screening methods, thereby making the drug discovery process more time and cost efficient.

Indexed as

drug discoveryhigh-throughput imagingmachine learning

Identifiers

PMID31217689
PMCPMC6563400
OpenAlexW2952777502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.